Brand Name | Status | Last Update |
---|---|---|
abecma | Biologic Licensing Application | 2025-03-26 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
multiple myeloma | — | D009101 | C90.0 |
Expiration | Code | ||
---|---|---|---|
idecabtagene vicleucel, Abecma, Celgene Corporation, a Bristol-Myers Squibb Company | |||
2028-03-26 | Orphan excl. |
Code | Description |
---|---|
Q2055 | Idecabtagene vicleucel, up to 460 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Multiple myeloma | D009101 | — | C90.0 | 53 | 34 | 7 | 1 | 10 | 90 |
Plasma cell neoplasms | D054219 | — | — | 50 | 30 | 7 | 1 | 7 | 82 |
Neoplasms | D009369 | — | C80 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Leukemia | D007938 | — | C95 | 2 | 4 | — | — | 1 | 6 |
Autoimmune diseases | D001327 | EFO_0000540 | M30-M36 | 5 | 1 | — | — | 1 | 6 |
Plasma cell leukemia | D007952 | — | C90.1 | 1 | 3 | — | — | 1 | 5 |
Lymphoma | D008223 | — | C85.9 | 2 | 1 | — | — | 1 | 3 |
Amyloidosis | D000686 | EFO_1001875 | E85 | 1 | 1 | — | — | 1 | 3 |
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | — | 1 | — | — | 1 | 2 |
B-cell lymphoma | D016393 | — | — | — | 1 | — | — | 1 | 2 |
Healthy volunteers/patients | — | — | — | 2 | 1 | — | — | — | 2 |
Lupus nephritis | D008181 | EFO_0005761 | — | 2 | 1 | — | — | — | 2 |
Nephritis | D009393 | — | N05 | 2 | 1 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | 4 | — | — | — | — | 4 |
Myasthenia gravis | D009157 | EFO_0004991 | G70.0 | 4 | — | — | — | — | 4 |
Vasculitis | D014657 | EFO_0006803 | M31 | 3 | — | — | — | — | 3 |
Anti-neutrophil cytoplasmic antibody-associated vasculitis | D056648 | — | I77.82 | 3 | — | — | — | — | 3 |
Hemolytic anemia autoimmune | D000744 | EFO_1001264 | D59.10 | 3 | — | — | — | — | 3 |
Hemolytic anemia | D000743 | — | D55-D59 | 3 | — | — | — | — | 3 |
Syndrome | D013577 | — | — | 2 | — | — | — | — | 2 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | — | — | — | 1 | 2 |
Immunoglobulin g4-related disease | D000077733 | — | D89.84 | 2 | — | — | — | — | 2 |
Multiple sclerosis | D009103 | EFO_0003885 | G35 | 2 | — | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Vaccine-preventable diseases | D000079263 | — | — | — | — | — | — | 1 | 1 |
B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | — | — | — | — | 1 | 1 |
Immunoglobulin light-chain amyloidosis | D000075363 | — | — | — | — | — | — | 1 | 1 |
Lymphoid leukemia | D007945 | — | C91 | — | — | — | — | 1 | 1 |
Drug common name | Idecabtagene vicleucel |
INN | idecabtagene vicleucel |
Description | Idecabtagene vicleucel, sold under the brand name Abecma, is a cell-based gene therapy to treat multiple myeloma.
|
Classification | Gene |
Drug class | Antineoplastic |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL4298199 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | 8PX1X7UG4D (ChemIDplus, GSRS) |